We developed a novel DC-directed lentivector, LV-GFP/SVGmu that could specifically transduce DC-SIGN-expressing cells with a high efficiency.
The DC- directed lentivector, LV-AEG/SVGmu, was also able to successfully transduce and express the fusion antigen Ag85A-E6-GFP in DC-SIGN-expressing cells.
A single footpad injection of LV-AEG/SVGmu could elicit significant elevated cellular and humoral immune responses in mice.
Hence, it can be considered as a novel candidate for vaccine research and immunotherapy in future.